01—Abstract
Summary
Summary of the 10-K filed February 22, 2022. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. is a biopharma technology platform company that licenses its rHuPH20 enzyme-based ENHANZE drug delivery technology to biopharmaceutical companies to convert IV drugs into subcutaneous formulations.
For 2021, total revenues were $443.3 milliona, up from $267.6 million in 2020. Royalties rose to $203.9 million from $88.6 million, driven mainly by DARZALEX FASPRO sales by Janssen and Phesgo sales by Roche. Product sales, net were $104.2 million, and revenues under collaborative agreements were $135.2 million.
Net income was $402.7 millionb, or $2.74 per diluted share, which includes a $154.2 million income tax benefit from the release of the valuation allowance on deferred tax assets. The filing states that Halozyme expects income tax expense to begin in 2022 at an estimated rate approximating statutory rates, which would significantly reduce net income. The balance sheet shows cash, cash equivalents and marketable securities of $740.9 million at December 31, 2021.
Total convertible note principal was $895.9 millionc, comprising $90.9 million of 1.25% notes due 2024 (classified as current) and $805.0 million of 0.25% notes due 2027. In March 2021, the company completed an induced conversion of $369.1 million of the 2024 notes. The company repurchased $350.1 million of common stock in 2021 and completed its $550.0 million program in October 2021.
In December 2021 it authorized a second program of up to $750.0 milliond over three years and entered an accelerated share repurchase of $150.0 million. A $75.0 million secured revolving credit facility with Bank of America was entered in December 2021 and was undrawn at year end. The filing describes a concentration of revenue and risk: Partner B accounted for 48% of 2021 total revenues and Partner A for 25%.
Management states that cash and marketable securities are sufficient to fund operations for at least the next twelve months. Key risks noted include dependence on collaborators, COVID-19 disruption, reliance on third-party contract manufacturers for bulk rHuPH20, and the reclassification of the 2024 notes to a current liability.
02—Key points
Key Highlights
- Total revenues rose to $443.3 million in 2021 from $267.6 million in 2020, with royalties of $203.9 million compared to $88.6 million.
- Net income was $402.7 million ($2.74 per diluted share), including a $154.2 million income tax benefit from releasing the valuation allowance on deferred tax assets.
- The company expects to begin recording income tax expense at approximately statutory rates from 2022, which would significantly reduce net income and net income per share.
- Cash, cash equivalents and marketable securities totaled $740.9 million at December 31, 2021, and management believes this is sufficient for at least the next twelve months.
- Total convertible notes principal was $895.9 million, and the 2024 notes ($90.9 million) are classified as a current liability because the conditional conversion feature was triggered.
- A second $750.0 million share repurchase program was authorized in December 2021, including a $150.0 million accelerated share repurchase.
- Partner B accounted for 48% of 2021 total revenues, and Partner A for 25%, indicating significant revenue concentration.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2021, Halozyme Therapeutics kept $0.91.
- Revenue$443.3M100.0%
- Cost of revenue−$81.4M18.4%
- Gross profit$361.9M81.6%
- Operating costs−$86.0M19.4%
- Operating income$275.9M62.2%
- Interest, other & tax$126.8M28.6%
- Net income$402.7M90.8%
Where FY2021 revenue went
$443.3M- Operating income: $275.9M, 62% of revenue
- Cost of revenue: $81.4M, 18% of revenue
- R&D: $35.7M, 8.0% of revenue
- SG&A: $50.3M, 11% of revenue
Kept 62% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 22, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $443.31M$267.59M | +65.7% |
| Cost of Revenue | $81.41M$43.37M | +87.7% |
| Gross Profit | $361.90M$224.23M | +61.4% |
| R&D Expenses | $35.67M$34.24M | +4.2% |
| SG&A Expenses | $50.32M$45.74M | +10.0% |
| Operating Expenses | $167.41M$123.34M | +35.7% |
| Operating Income | $275.90M$144.25M | +91.3% |
| Interest Expense | $7.53M$20.38M | −63.1% |
| Net Income | $402.71M$129.09M | +212.0% |
| EPS (Basic) | $2.86$0.95 | +201.1% |
| EPS (Diluted) | $2.74$0.91 | +201.1% |
| Shares Outstanding (Basic) | 140.65M136.21M | +3.3% |
| Shares Outstanding (Diluted) | 146.80M141.46M | +3.8% |
05—Questions
Frequently Asked Questions
Why did net income rise so sharply in 2021?
Net income was $402.7 million in 2021 compared with $129.1 million in 2020. The filing attributes the increase largely to higher royalties from DARZALEX FASPRO and Phesgo, and to a $154.2 million income tax benefit from releasing the valuation allowance on deferred tax assets. The company states that comparisons to these 2021 amounts are not indicative of future profitability trends.
What happens to the convertible notes?
The 2024 notes ($90.9 million principal) are classified as current because their conditional conversion feature was triggered, and the company has elected to settle principal in cash. In March 2021 it completed an induced conversion of $369.1 million of these notes. The 2027 notes ($805.0 million principal, 0.25% coupon) mature on March 1, 2027 and were not convertible as of December 31, 2021.
How is the company returning capital to shareholders?
The company completed its $550.0 million repurchase program in October 2021, repurchasing 22.3 million shares in total. In December 2021 it authorized a $750.0 million program over three years and entered a $150.0 million accelerated share repurchase, of which 3.5 million shares were initially delivered. The company has never paid dividends and does not expect to in the foreseeable future.
What are the main risks to the company's revenue?
The filing highlights dependence on collaborators' development and commercialization efforts, the risk of regulatory delays or rejections for partner products, reliance on third-party contract manufacturers for bulk rHuPH20, and COVID-19 disruption. Revenue concentration is also significant, with Partner B at 48% and Partner A at 25% of 2021 total revenues.
06—Continue